US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

InflaRx N.V.

2.12

+0.03001.44%

Post-market: 2.140.0200+0.94%19:30 EDT

Volume:545.79K

Turnover:1.17M

Market Cap:312.26M

PE:-3.71

High:2.20

Open:2.15

Low:2.10

Close:2.09

52wk High:2.95

52wk Low:0.7984

Shares:147.29M

Float Shares:98.11M

Volume Ratio:1.09

T/O Rate:0.56%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5715

EPS(LYR):-0.7963

ROE:-38.52%

ROA:-18.54%

PB:1.85

PE(LYR):-2.66

Loading ...

Overview Company News Filings

Guggenheim Reaffirms Their Buy Rating on InflaRx (IFRX)

InflaRx presents vilobelimab data

InflaRx vilobelimab Phase 3 pyoderma gangrenosum trial ends early for futility

InflaRx Is Maintained at Buy by Guggenheim

InflaRx price target lowered to $14 from $22 at Guggenheim

Analysts’ Opinions Are Mixed on These Healthcare Stocks: InflaRx (IFRX) and Kuros Biosciences (OtherCSBTF)

InflaRx NV reports results for the quarter ended December 31 - Earnings Summary

InflaRx Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $(39.501K) Miss $230.000K Estimate

Benzinga Earnings

InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year

InflaRx FY 2025 net loss narrows 9.8% to EUR 45.63 million

Press Release: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

InflaRx N.V. Director Mark Kubler Files Initial Statement of Beneficial Ownership

InflaRx N.V. director Anthony S. Gibney files initial beneficial ownership statement

InflaRx N.V. Director Hege Hellstrom Files Initial Beneficial Ownership Statement

Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting

InflaRx N.V. Chief Scientific Officer Guo Renfeng files initial beneficial ownership statement

InflaRx N.V. SVP Derval OCarroll Files Initial Beneficial Ownership Statement

InflaRx CEO and Director Niels Riedemann Files Initial Beneficial Ownership Statement

InflaRx NV CFO Thomas Taapken files initial beneficial ownership statement

InflaRx to present Phase 3 vilobelimab data in pyoderma gangrenosum at AAD annual meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/IFRX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IFRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IFRX\",,,,,undefined,":{"symbol":"IFRX","market":"US","secType":"STK","nameCN":"InflaRx N.V.","latestPrice":2.12,"timestamp":1789416000000,"preClose":2.09,"halted":0,"volume":545790,"hourTrading":{"tag":"盘后","latestPrice":2.14,"preClose":2.12,"latestTime":"19:30 EDT","volume":2053,"amount":4358.502,"timestamp":1789428600381,"change":0.02,"changeRate":0.009434,"amplitude":0.009434},"delay":0,"changeRate":0.014354066985646053,"floatShares":98114700,"shares":147292900,"eps":-0.5715,"marketStatus":"Closed","change":0.03,"latestTime":"09-14 16:00:00 EDT","open":2.15,"high":2.2,"low":2.1,"amount":1168473.951624,"amplitude":0.047847,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.5715,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1510117200000,"exchange":"NASDAQ","adjPreClose":2.09,"preHourTrading":{"tag":"盘前","latestPrice":2.15,"preClose":2.09,"latestTime":"09:25 EDT","volume":2781,"amount":5949.232002,"timestamp":1789392340263,"change":0.06,"changeRate":0.028708,"amplitude":0.043062},"postHourTrading":{"tag":"盘后","latestPrice":2.14,"preClose":2.12,"latestTime":"19:30 EDT","volume":2053,"amount":4358.502,"timestamp":1789428600381,"change":0.02,"changeRate":0.009434,"amplitude":0.009434},"volumeRatio":1.087136,"impliedVol":0.8111,"impliedVolPercentile":0.3147},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IFRX\",,,,,undefined,":{"symbol":"IFRX","floatShares":98114700,"roa":"-18.54%","roe":"-38.52%","lyrEps":-0.796269,"volumeRatio":1.087136,"shares":147292900,"dividePrice":0,"high":2.2,"amplitude":0.047847,"preClose":2.09,"low":2.1,"week52Low":0.7984,"pbRate":"1.85","psRate":"-26772.53","week52High":2.9489,"institutionHeld":0,"latestPrice":2.12,"eps":-0.5715,"divideRate":0,"volume":545790,"delay":0,"ttmEps":-0.5715,"open":2.15,"prevYearClose":1.01,"prevWeekClose":2.09,"prevMonthClose":2.13,"prevQuarterClose":2.24,"fiveDayClose":2.22,"twentyDayClose":2.04,"sixtyDayClose":1.82},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IFRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"IFRX","fiscalQuarterEnding":"2026/06","expectedEps":-0.08,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.11},{"date":"2026-05-07","symbol":"IFRX","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2026/03","expectedEps":-0.17,"defaultRemindTime":1778140800000,"name":null,"time":"Pre-MKt","dateTimestamp":1778126400000,"actualEps":null},{"market":"US","date":"2026-03-19","symbol":"IFRX","fiscalQuarterEnding":"2025/12","expectedEps":-0.18,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773892800000,"reportTimeType":"pre","actualEps":-0.17},{"market":"US","date":"2025-11-10","symbol":"IFRX","fiscalQuarterEnding":"2025/09","expectedEps":-0.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.16},{"market":"US","date":"2025-08-07","symbol":"IFRX","fiscalQuarterEnding":"2025/06","expectedEps":-0.24,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IFRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IFRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5556,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1784779200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/IFRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"IFRX","date":"2026-09-11","current":-3.709536,"percent":0.088816,"low":-9.450046,"twenty":-3.989551,"median":-2.314372,"eighty":-1.540877,"high":-0.61166,"avg":-2.964843,"sd":1.998688,"marketCap":302104853},"quantilePoints":[{"date":"2021-09-17","current":-2.80593,"twenty":-25.674949,"median":-3.397053,"eighty":-2.130135,"marketCap":120628541},{"date":"2021-09-24","current":-2.740723,"twenty":-25.665585,"median":-3.389807,"eighty":-2.134706,"marketCap":117535502},{"date":"2021-10-01","current":-2.664251,"twenty":-25.645992,"median":-3.376783,"eighty":-2.138732,"marketCap":113116874},{"date":"2021-10-08","current":-2.804412,"twenty":-25.638419,"median":-3.369345,"eighty":-2.139942,"marketCap":118861090},{"date":"2021-10-15","current":-2.568797,"twenty":-25.59942,"median":-3.355287,"eighty":-2.15103,"marketCap":109140109},{"date":"2021-10-22","current":-3.059811,"twenty":-25.561641,"median":-3.349052,"eighty":-2.154896,"marketCap":130349523},{"date":"2021-10-29","current":-4.423919,"twenty":-25.544343,"median":-3.348306,"eighty":-2.158087,"marketCap":187349822},{"date":"2021-11-05","current":-4.251839,"twenty":-25.536207,"median":-3.352563,"eighty":-2.163381,"marketCap":205466197},{"date":"2021-11-12","current":-5.149963,"twenty":-25.532701,"median":-3.369298,"eighty":-2.165514,"marketCap":246559436},{"date":"2021-11-19","current":-4.442446,"twenty":-25.494082,"median":-3.373909,"eighty":-2.169524,"marketCap":210326688},{"date":"2021-11-26","current":-4.743245,"twenty":-25.480025,"median":-3.383633,"eighty":-2.171417,"marketCap":224466297},{"date":"2021-12-03","current":-3.8471,"twenty":-25.476764,"median":-3.39115,"eighty":-2.172284,"marketCap":181605606},{"date":"2021-12-10","current":-3.950486,"twenty":-25.466679,"median":-3.407313,"eighty":-2.174154,"marketCap":186907960},{"date":"2021-12-17","current":-3.992006,"twenty":-25.456835,"median":-3.415357,"eighty":-2.176712,"marketCap":188233548},{"date":"2021-12-23","current":-4.34175,"twenty":-25.447224,"median":-3.439152,"eighty":-2.178157,"marketCap":205466197},{"date":"2021-12-31","current":-4.422329,"twenty":-25.434421,"median":-3.460422,"eighty":-2.181429,"marketCap":210326688},{"date":"2022-01-07","current":-3.615004,"twenty":-25.4299,"median":-3.469026,"eighty":-2.186377,"marketCap":171442762},{"date":"2022-01-14","current":-3.931443,"twenty":-25.423348,"median":-3.476311,"eighty":-2.188634,"marketCap":187791685},{"date":"2022-01-21","current":-3.27922,"twenty":-25.415798,"median":-3.480271,"eighty":-2.18983,"marketCap":155535702},{"date":"2022-01-28","current":-3.332032,"twenty":-25.405586,"median":-3.472316,"eighty":-2.191659,"marketCap":155535702},{"date":"2022-02-04","current":-3.277911,"twenty":-25.393185,"median":-3.463394,"eighty":-2.191987,"marketCap":156861290},{"date":"2022-02-11","current":-3.094239,"twenty":-25.349416,"median":-3.457906,"eighty":-2.192343,"marketCap":147582171},{"date":"2022-02-18","current":-2.908888,"twenty":-25.342061,"median":-3.438284,"eighty":-2.19268,"marketCap":137861190},{"date":"2022-02-25","current":-2.822869,"twenty":-25.330025,"median":-3.426102,"eighty":-2.193365,"marketCap":133000699},{"date":"2022-03-04","current":-2.042583,"twenty":-25.326961,"median":-3.408072,"eighty":-2.192509,"marketCap":93233048},{"date":"2022-03-11","current":-1.881926,"twenty":-25.319085,"median":-3.394102,"eighty":-2.189491,"marketCap":86163244},{"date":"2022-03-18","current":-2.091797,"twenty":-25.313085,"median":-3.389039,"eighty":-2.185207,"marketCap":96767951},{"date":"2022-03-25","current":-2.212947,"twenty":-25.309822,"median":-3.373909,"eighty":-2.178911,"marketCap":110951445},{"date":"2022-04-01","current":-1.667593,"twenty":-25.302123,"median":-3.369298,"eighty":-2.172439,"marketCap":83987149},{"date":"2022-04-08","current":-1.558658,"twenty":-25.300371,"median":-3.359638,"eighty":-2.164523,"marketCap":77356585},{"date":"2022-04-14","current":-1.613479,"twenty":-25.284057,"median":-3.352563,"eighty":-2.153506,"marketCap":79566773},{"date":"2022-04-22","current":-1.590703,"twenty":-25.274805,"median":-3.348306,"eighty":-2.139942,"marketCap":78240660},{"date":"2022-04-29","current":-1.553514,"twenty":-25.247442,"median":-3.341568,"eighty":-2.130135,"marketCap":74704359},{"date":"2022-05-06","current":-1.463033,"twenty":-25.232905,"median":-3.334919,"eighty":-2.118001,"marketCap":70726020},{"date":"2022-05-13","current":-1.158755,"twenty":-25.216013,"median":-3.326309,"eighty":-2.104355,"marketCap":64537493},{"date":"2022-05-20","current":-1.127654,"twenty":-25.153392,"median":-3.312666,"eighty":-2.090537,"marketCap":63653418},{"date":"2022-05-27","current":-1.133538,"twenty":-25.123387,"median":-3.307821,"eighty":-2.078473,"marketCap":64979531},{"date":"2022-06-03","current":-1.133052,"twenty":-25.102901,"median":-3.297547,"eighty":-2.071719,"marketCap":64979531},{"date":"2022-06-10","current":-1.099107,"twenty":-25.078955,"median":-3.285676,"eighty":-2.064881,"marketCap":61885268},{"date":"2022-06-17","current":-0.95534,"twenty":-25.058012,"median":-3.278566,"eighty":-2.059013,"marketCap":53486553},{"date":"2022-06-24","current":-0.61166,"twenty":-25.013779,"median":-3.274146,"eighty":-2.050697,"marketCap":34523138},{"date":"2022-07-01","current":-1.143714,"twenty":-24.953195,"median":-3.27019,"eighty":-2.039731,"marketCap":63653418},{"date":"2022-07-08","current":-1.249984,"twenty":-24.940061,"median":-3.266364,"eighty":-2.028029,"marketCap":68073795},{"date":"2022-07-15","current":-1.105244,"twenty":-24.912512,"median":-3.253607,"eighty":-2.016954,"marketCap":59675080},{"date":"2022-07-22","current":-1.090969,"twenty":-24.825431,"median":-3.232562,"eighty":-1.98678,"marketCap":59675080},{"date":"2022-07-29","current":-2.219243,"twenty":-24.705558,"median":-3.220144,"eighty":-1.924555,"marketCap":121118310},{"date":"2022-08-05","current":-3.310261,"twenty":-24.665355,"median":-3.208176,"eighty":-1.952888,"marketCap":128632950},{"date":"2022-08-12","current":-3.369138,"twenty":-24.623821,"median":-3.226312,"eighty":-1.980182,"marketCap":132169251},{"date":"2022-08-19","current":-2.876794,"twenty":-24.618574,"median":-3.208176,"eighty":-1.98678,"marketCap":110509407},{"date":"2022-08-26","current":-2.62393,"twenty":-24.606349,"median":-3.198154,"eighty":-2.009536,"marketCap":100342542},{"date":"2022-09-02","current":-2.648776,"twenty":-24.583084,"median":-3.186455,"eighty":-2.011689,"marketCap":101668654},{"date":"2022-09-09","current":-3.268037,"twenty":-24.575807,"median":-3.180921,"eighty":-2.016029,"marketCap":125538686},{"date":"2022-09-16","current":-3.112552,"twenty":-24.525387,"median":-3.168258,"eighty":-2.016818,"marketCap":119350160},{"date":"2022-09-23","current":-2.519124,"twenty":-24.51136,"median":-3.149642,"eighty":-2.017498,"marketCap":93711977},{"date":"2022-09-30","current":-3.110486,"twenty":-24.503768,"median":-3.141488,"eighty":-2.023142,"marketCap":116697934},{"date":"2022-10-07","current":-3.001762,"twenty":-24.499937,"median":-3.125003,"eighty":-2.026815,"marketCap":112277558},{"date":"2022-10-14","current":-2.833329,"twenty":-24.463679,"median":-3.11616,"eighty":-2.027695,"marketCap":105646993},{"date":"2022-10-21","current":-2.968518,"twenty":-24.434266,"median":-3.112552,"eighty":-2.029366,"marketCap":111393482},{"date":"2022-10-28","current":-3.044242,"twenty":-24.387783,"median":-3.104843,"eighty":-2.031686,"marketCap":115813859},{"date":"2022-11-04","current":-2.925419,"twenty":-24.386265,"median":-3.100143,"eighty":-2.034524,"marketCap":110951445},{"date":"2022-11-11","current":-3.360927,"twenty":-24.374133,"median":-3.104843,"eighty":-2.038158,"marketCap":118466084},{"date":"2022-11-18","current":-3.187327,"twenty":-24.357612,"median":-3.106216,"eighty":-2.04209,"marketCap":112719595},{"date":"2022-11-25","current":-3.114145,"twenty":-24.321314,"median":-3.103471,"eighty":-2.042484,"marketCap":110509407},{"date":"2022-12-02","current":-3.199416,"twenty":-24.305952,"median":-3.109484,"eighty":-2.045113,"marketCap":114487746},{"date":"2022-12-09","current":-2.839171,"twenty":-24.296418,"median":-3.103471,"eighty":-2.048262,"marketCap":102110692},{"date":"2022-12-16","current":-2.626368,"twenty":-24.268656,"median":-3.098225,"eighty":-2.052502,"marketCap":95038090},{"date":"2022-12-23","current":-3.963354,"twenty":-24.249087,"median":-3.100143,"eighty":-2.05414,"marketCap":143662229},{"date":"2022-12-30","current":-3.757141,"twenty":-24.236402,"median":-3.103471,"eighty":-2.05494,"marketCap":137031665},{"date":"2023-01-06","current":-3.429325,"twenty":-24.187068,"median":-3.103471,"eighty":-2.05494,"marketCap":124212574},{"date":"2023-01-13","current":-3.148676,"twenty":-24.119807,"median":-3.103471,"eighty":-2.05494,"marketCap":116255896},{"date":"2023-01-20","current":-2.87463,"twenty":-24.060794,"median":-3.095243,"eighty":-2.05494,"marketCap":106310050},{"date":"2023-01-27","current":-2.684699,"twenty":-23.889509,"median":-3.081171,"eighty":-2.05494,"marketCap":99458466},{"date":"2023-02-03","current":-2.625894,"twenty":-23.753924,"median":-3.075373,"eighty":-2.05494,"marketCap":97248278},{"date":"2023-02-10","current":-2.437904,"twenty":-23.637734,"median":-3.064648,"eighty":-2.05494,"marketCap":88849563},{"date":"2023-02-17","current":-2.733077,"twenty":-23.443338,"median":-3.059811,"eighty":-2.05494,"marketCap":99458466},{"date":"2023-02-24","current":-2.504414,"twenty":-23.240436,"median":-3.05296,"eighty":-2.05494,"marketCap":90175676},{"date":"2023-03-03","current":-2.223958,"twenty":-23.091745,"median":-3.042742,"eighty":-2.05494,"marketCap":80450848},{"date":"2023-03-10","current":-2.185996,"twenty":-22.971614,"median":-3.031527,"eighty":-2.05494,"marketCap":79566773},{"date":"2023-03-17","current":-2.017049,"twenty":-22.749108,"median":-3.015708,"eighty":-2.053956,"marketCap":73378246},{"date":"2023-03-24","current":-2.536982,"twenty":-22.567429,"median":-3.002572,"eighty":-2.051599,"marketCap":80466773},{"date":"2023-03-31","current":-2.707242,"twenty":-22.293774,"median":-2.985327,"eighty":-2.052502,"marketCap":86725300},{"date":"2023-04-06","current":-8.468992,"twenty":-22.221188,"median":-2.980368,"eighty":-2.050697,"marketCap":272692954},{"date":"2023-04-19","current":-7.539816,"twenty":-21.900043,"median":-2.966913,"eighty":-2.045113,"marketCap":243679193},{"date":"2023-04-28","current":-8.425592,"twenty":-21.574969,"median":-2.964258,"eighty":-2.043848,"marketCap":273807214},{"date":"2023-05-05","current":-8.149129,"twenty":-21.326308,"median":-2.964258,"eighty":-2.043848,"marketCap":264385891},{"date":"2023-05-12","current":-8.961759,"twenty":-21.165358,"median":-2.964258,"eighty":-2.043848,"marketCap":288528032},{"date":"2023-05-19","current":-8.105007,"twenty":-20.576815,"median":-2.964258,"eighty":-2.043848,"marketCap":257319898},{"date":"2023-05-26","current":-7.634536,"twenty":-18.895891,"median":-2.964258,"eighty":-2.043848,"marketCap":241421415},{"date":"2023-06-02","current":-8.897592,"twenty":-17.2313,"median":-2.964258,"eighty":-2.043848,"marketCap":253786902},{"date":"2023-06-09","current":-8.238655,"twenty":-8.997075,"median":-2.964258,"eighty":-2.043848,"marketCap":235827504},{"date":"2023-06-16","current":-9.028798,"twenty":-8.93681,"median":-2.964258,"eighty":-2.043848,"marketCap":262030560},{"date":"2023-06-23","current":-9.140768,"twenty":-8.899027,"median":-2.963209,"eighty":-2.043216,"marketCap":266152389},{"date":"2023-06-30","current":-9.039015,"twenty":-8.897592,"median":-2.962755,"eighty":-2.042583,"marketCap":261441727},{"date":"2023-07-07","current":-7.957828,"twenty":-8.77461,"median":-2.962755,"eighty":-2.042583,"marketCap":229644760},{"date":"2023-07-14","current":-8.574185,"twenty":-8.60592,"median":-2.962755,"eighty":-2.042583,"marketCap":254964567},{"date":"2023-07-21","current":-8.113503,"twenty":-8.47995,"median":-2.962755,"eighty":-2.042583,"marketCap":240243749},{"date":"2023-07-28","current":-8.208184,"twenty":-8.435717,"median":-2.962755,"eighty":-2.042583,"marketCap":239654917},{"date":"2023-08-04","current":-8.299584,"twenty":-8.360313,"median":-2.962755,"eighty":-2.042583,"marketCap":241421415},{"date":"2023-08-11","current":-6.068497,"twenty":-8.239877,"median":-2.962755,"eighty":-2.042583,"marketCap":235533088},{"date":"2023-08-18","current":-5.82274,"twenty":-8.188318,"median":-2.962755,"eighty":-2.042583,"marketCap":223167600},{"date":"2023-08-25","current":-5.909797,"twenty":-8.105007,"median":-2.962755,"eighty":-2.042583,"marketCap":225522931},{"date":"2023-09-01","current":-6.086379,"twenty":-7.942756,"median":-2.962301,"eighty":-2.042484,"marketCap":232588924},{"date":"2023-09-08","current":-6.122042,"twenty":-7.841561,"median":-2.962301,"eighty":-2.042484,"marketCap":230822426},{"date":"2023-09-15","current":-6.047691,"twenty":-7.657546,"median":-2.962301,"eighty":-2.042484,"marketCap":227289429},{"date":"2023-09-22","current":-4.87418,"twenty":-7.215475,"median":-2.960275,"eighty":-2.042386,"marketCap":183126975},{"date":"2023-09-29","current":-4.665817,"twenty":-6.271729,"median":-2.960275,"eighty":-2.042386,"marketCap":173705652},{"date":"2023-10-06","current":-4.095273,"twenty":-6.07565,"median":-2.960275,"eighty":-2.042386,"marketCap":151918841},{"date":"2023-10-13","current":-3.864893,"twenty":-5.857563,"median":-2.960275,"eighty":-2.042386,"marketCap":143675183},{"date":"2023-10-20","current":-3.286668,"twenty":-5.646626,"median":-2.960275,"eighty":-2.042386,"marketCap":122477205},{"date":"2023-10-27","current":-2.697868,"twenty":-5.537504,"median":-2.950514,"eighty":-2.04209,"marketCap":100101562},{"date":"2023-11-03","current":-2.233806,"twenty":-5.197421,"median":-2.928023,"eighty":-2.04209,"marketCap":82436580},{"date":"2023-11-10","current":-2.087155,"twenty":-4.907963,"median":-2.91242,"eighty":-2.04209,"marketCap":77725919},{"date":"2023-11-17","current":-2.261025,"twenty":-4.743245,"median":-2.905286,"eighty":-2.034524,"marketCap":85380744},{"date":"2023-11-24","current":-2.252183,"twenty":-4.665817,"median":-2.892865,"eighty":-2.034524,"marketCap":85380744},{"date":"2023-12-01","current":-2.096632,"twenty":-4.532206,"median":-2.879719,"eighty":-2.031686,"marketCap":79492417},{"date":"2023-12-08","current":-2.197999,"twenty":-4.48737,"median":-2.868186,"eighty":-2.032254,"marketCap":82436580},{"date":"2023-12-15","current":-2.110521,"twenty":-4.438457,"median":-2.833849,"eighty":-2.032254,"marketCap":80670082},{"date":"2023-12-22","current":-2.280481,"twenty":-4.370666,"median":-2.82501,"eighty":-2.031763,"marketCap":87147242},{"date":"2023-12-29","current":-2.538435,"twenty":-4.33424,"median":-2.816208,"eighty":-2.031686,"marketCap":97746231},{"date":"2024-01-05","current":-2.828463,"twenty":-4.286188,"median":-2.805171,"eighty":-2.031222,"marketCap":107756387},{"date":"2024-01-12","current":-2.707482,"twenty":-4.256229,"median":-2.79763,"eighty":-2.031222,"marketCap":103045726},{"date":"2024-01-19","current":-2.494382,"twenty":-4.232858,"median":-2.773571,"eighty":-2.030758,"marketCap":94213235},{"date":"2024-01-26","current":-2.344327,"twenty":-4.195043,"median":-2.765202,"eighty":-2.031222,"marketCap":88324908},{"date":"2024-02-02","current":-2.654313,"twenty":-4.16251,"median":-2.743527,"eighty":-2.031222,"marketCap":100101562},{"date":"2024-02-09","current":-2.486219,"twenty":-4.136824,"median":-2.732222,"eighty":-2.031222,"marketCap":93035569},{"date":"2024-02-16","current":-2.42458,"twenty":-4.095212,"median":-2.710198,"eighty":-2.031222,"marketCap":90680238},{"date":"2024-02-23","current":-2.301923,"twenty":-4.077605,"median":-2.703082,"eighty":-2.031222,"marketCap":86558409},{"date":"2024-03-01","current":-2.789171,"twenty":-4.072563,"median":-2.697868,"eighty":-2.031686,"marketCap":104812224},{"date":"2024-03-08","current":-2.572738,"twenty":-4.024419,"median":-2.697241,"eighty":-2.031686,"marketCap":97746231},{"date":"2024-03-15","current":-2.363742,"twenty":-4.006418,"median":-2.688162,"eighty":-2.031686,"marketCap":89502573},{"date":"2024-03-22","current":-1.957166,"twenty":-3.989235,"median":-2.683334,"eighty":-2.029366,"marketCap":90680238},{"date":"2024-03-28","current":-1.96758,"twenty":-3.977045,"median":-2.670879,"eighty":-2.026815,"marketCap":90680238},{"date":"2024-04-05","current":-1.981938,"twenty":-3.964341,"median":-2.658011,"eighty":-2.01666,"marketCap":91857904},{"date":"2024-04-12","current":-1.984369,"twenty":-3.932271,"median":-2.654637,"eighty":-1.983883,"marketCap":90680238},{"date":"2024-04-19","current":-1.630704,"twenty":-3.866737,"median":-2.638291,"eighty":-1.97026,"marketCap":74192922},{"date":"2024-04-26","current":-1.790703,"twenty":-3.836036,"median":-2.634291,"eighty":-1.962479,"marketCap":81847748},{"date":"2024-05-03","current":-1.780105,"twenty":-3.78565,"median":-2.628724,"eighty":-1.946126,"marketCap":81258915},{"date":"2024-05-10","current":-1.590155,"twenty":-3.773538,"median":-2.625321,"eighty":-1.897734,"marketCap":70659926},{"date":"2024-05-17","current":-1.904668,"twenty":-3.753351,"median":-2.61868,"eighty":-1.886655,"marketCap":85380744},{"date":"2024-05-24","current":-1.952316,"twenty":-3.735549,"median":-2.606627,"eighty":-1.886655,"marketCap":87147242},{"date":"2024-05-31","current":-1.882889,"twenty":-3.684127,"median":-2.593785,"eighty":-1.882889,"marketCap":84203078},{"date":"2024-06-07","current":-2.112539,"twenty":-3.653656,"median":-2.588348,"eighty":-1.881926,"marketCap":94802067},{"date":"2024-06-14","current":-2.016149,"twenty":-3.654543,"median":-2.588093,"eighty":-1.881261,"marketCap":89502573},{"date":"2024-06-21","current":-1.971968,"twenty":-3.65543,"median":-2.585869,"eighty":-1.880596,"marketCap":87147242},{"date":"2024-06-28","current":-2.227273,"twenty":-3.658092,"median":-2.588093,"eighty":-1.878601,"marketCap":98335064},{"date":"2024-07-05","current":-2.152746,"twenty":-3.658092,"median":-2.584246,"eighty":-1.878601,"marketCap":95979733},{"date":"2024-07-12","current":-2.154011,"twenty":-3.658092,"median":-2.579459,"eighty":-1.878601,"marketCap":96568566},{"date":"2024-07-15","current":-2.132266,"twenty":-3.658092,"median":-2.579459,"eighty":-1.878601,"marketCap":95979733},{"date":"2024-08-02","current":-2.012243,"twenty":-3.698487,"median":-2.587838,"eighty":-1.867194,"marketCap":89502573},{"date":"2024-08-09","current":-1.542577,"twenty":-3.698487,"median":-2.587838,"eighty":-1.851127,"marketCap":78903584},{"date":"2024-08-16","current":-1.543577,"twenty":-3.698487,"median":-2.587838,"eighty":-1.84579,"marketCap":79492417},{"date":"2024-08-23","current":-1.707365,"twenty":-3.698487,"median":-2.587838,"eighty":-1.84579,"marketCap":88913740},{"date":"2024-08-30","current":-1.882183,"twenty":-3.698487,"median":-2.587838,"eighty":-1.847445,"marketCap":97746231},{"date":"2024-09-06","current":-1.77856,"twenty":-3.698487,"median":-2.587838,"eighty":-1.847445,"marketCap":92446737},{"date":"2024-09-13","current":-1.638886,"twenty":-3.698487,"median":-2.587838,"eighty":-1.847445,"marketCap":84791911},{"date":"2024-09-20","current":-1.7139,"twenty":-3.698487,"median":-2.587838,"eighty":-1.847445,"marketCap":89502573},{"date":"2024-09-27","current":-1.730455,"twenty":-3.698487,"median":-2.587838,"eighty":-1.847445,"marketCap":90680238},{"date":"2024-10-04","current":-1.77879,"twenty":-3.698487,"median":-2.587838,"eighty":-1.847445,"marketCap":91857904},{"date":"2024-10-11","current":-1.678334,"twenty":-3.698487,"median":-2.587838,"eighty":-1.847445,"marketCap":85969577},{"date":"2024-10-18","current":-1.797756,"twenty":-3.698487,"median":-2.587838,"eighty":-1.847445,"marketCap":91269071},{"date":"2024-10-25","current":-1.86037,"twenty":-3.698487,"median":-2.587838,"eighty":-1.849356,"marketCap":94213235},{"date":"2024-10-31","current":-1.816024,"twenty":-3.698487,"median":-2.587838,"eighty":-1.849356,"marketCap":92446737},{"date":"2024-11-08","current":-1.75819,"twenty":-3.703273,"median":-2.588093,"eighty":-1.853721,"marketCap":88913740},{"date":"2024-11-15","current":-1.986236,"twenty":-3.703273,"median":-2.588093,"eighty":-1.85898,"marketCap":119533042},{"date":"2024-11-22","current":-2.032862,"twenty":-3.703273,"median":-2.588093,"eighty":-1.873049,"marketCap":121299540},{"date":"2024-11-29","current":-2.413842,"twenty":-3.703273,"median":-2.588093,"eighty":-1.881058,"marketCap":144852849},{"date":"2024-12-06","current":-2.409258,"twenty":-3.703273,"median":-2.588093,"eighty":-1.888141,"marketCap":144852849},{"date":"2024-12-13","current":-2.279807,"twenty":-3.703273,"median":-2.588093,"eighty":-1.905561,"marketCap":136020358},{"date":"2024-12-20","current":-2.123768,"twenty":-3.703273,"median":-2.588093,"eighty":-1.919808,"marketCap":125421369},{"date":"2024-12-27","current":-2.594259,"twenty":-3.703273,"median":-2.590889,"eighty":-1.928389,"marketCap":153685339},{"date":"2025-01-03","current":-2.523482,"twenty":-3.703273,"median":-2.593524,"eighty":-1.945481,"marketCap":147208180},{"date":"2025-01-10","current":-2.342961,"twenty":-3.70806,"median":-2.593617,"eighty":-1.957166,"marketCap":137198023},{"date":"2025-01-17","current":-2.564185,"twenty":-3.70806,"median":-2.593617,"eighty":-1.96758,"marketCap":150152343},{"date":"2025-01-24","current":-2.356442,"twenty":-3.70806,"median":-2.593617,"eighty":-1.978631,"marketCap":139553354},{"date":"2025-01-31","current":-2.353498,"twenty":-3.70806,"median":-2.593617,"eighty":-1.994331,"marketCap":139553354},{"date":"2025-02-07","current":-2.534146,"twenty":-3.70806,"median":-2.593617,"eighty":-2.012243,"marketCap":149563510},{"date":"2025-02-14","current":-2.676169,"twenty":-3.70806,"median":-2.594259,"eighty":-2.017073,"marketCap":158984834},{"date":"2025-02-21","current":-1.830033,"twenty":-3.70806,"median":-2.594259,"eighty":-2.016149,"marketCap":108934053},{"date":"2025-02-28","current":-1.342976,"twenty":-3.70806,"median":-2.594259,"eighty":-2.007413,"marketCap":79492417},{"date":"2025-03-07","current":-1.156608,"twenty":-3.708133,"median":-2.594022,"eighty":-1.983883,"marketCap":71248759},{"date":"2025-03-14","current":-1.095804,"twenty":-3.708133,"median":-2.594022,"eighty":-1.983883,"marketCap":67715762},{"date":"2025-03-21","current":-1.484361,"twenty":-3.708133,"median":-2.594022,"eighty":-1.983883,"marketCap":74192922},{"date":"2025-03-28","current":-1.699421,"twenty":-3.708133,"median":-2.594022,"eighty":-1.983883,"marketCap":84502137},{"date":"2025-04-04","current":-1.392072,"twenty":-3.708133,"median":-2.593524,"eighty":-1.978954,"marketCap":70981795},{"date":"2025-04-11","current":-1.180921,"twenty":-3.70806,"median":-2.588348,"eighty":-1.96758,"marketCap":60841539},{"date":"2025-04-17","current":-1.355089,"twenty":-3.70806,"median":-2.587838,"eighty":-1.958598,"marketCap":70981795},{"date":"2025-04-25","current":-1.706059,"twenty":-3.708133,"median":-2.586854,"eighty":-1.944521,"marketCap":89234257},{"date":"2025-05-02","current":-2.407629,"twenty":-3.708133,"median":-2.583083,"eighty":-1.926392,"marketCap":125063163},{"date":"2025-05-09","current":-2.118244,"twenty":-3.708133,"median":-2.577703,"eighty":-1.926392,"marketCap":106810701},{"date":"2025-05-16","current":-2.410655,"twenty":-3.708133,"median":-2.573155,"eighty":-1.926392,"marketCap":120589891},{"date":"2025-05-23","current":-2.443597,"twenty":-3.679696,"median":-2.568267,"eighty":-1.926392,"marketCap":123299776},{"date":"2025-05-30","current":-1.13339,"twenty":-3.647428,"median":-2.563851,"eighty":-1.913307,"marketCap":57591835},{"date":"2025-06-06","current":-1.123178,"twenty":-3.626423,"median":-2.55507,"eighty":-1.889126,"marketCap":57517313},{"date":"2025-06-13","current":-1.047083,"twenty":-3.626423,"median":-2.541295,"eighty":-1.880393,"marketCap":54197704},{"date":"2025-06-20","current":-1.054136,"twenty":-3.62668,"median":-2.538033,"eighty":-1.875322,"marketCap":54062209},{"date":"2025-06-27","current":-1.078148,"twenty":-3.62668,"median":-2.538033,"eighty":-1.847382,"marketCap":56406260},{"date":"2025-07-03","current":-1.03345,"twenty":-3.62668,"median":-2.538033,"eighty":-1.835407,"marketCap":54360297},{"date":"2025-07-11","current":-1.160295,"twenty":-3.62668,"median":-2.538033,"eighty":-1.822354,"marketCap":60647230},{"date":"2025-07-18","current":-1.134508,"twenty":-3.62668,"median":-2.538033,"eighty":-1.809629,"marketCap":58797734},{"date":"2025-07-25","current":-1.094112,"twenty":-3.62668,"median":-2.538033,"eighty":-1.799033,"marketCap":57591835},{"date":"2025-08-01","current":-1.198497,"twenty":-3.62668,"median":-2.538033,"eighty":-1.790625,"marketCap":61311152},{"date":"2025-08-08","current":-1.048287,"twenty":-3.62668,"median":-2.538033,"eighty":-1.779579,"marketCap":55220685},{"date":"2025-08-15","current":-1.062121,"twenty":-3.62668,"median":-2.538033,"eighty":-1.773402,"marketCap":56047200},{"date":"2025-08-22","current":-1.15665,"twenty":-3.62668,"median":-2.538033,"eighty":-1.764837,"marketCap":60836922},{"date":"2025-08-29","current":-1.500694,"twenty":-3.62668,"median":-2.538033,"eighty":-1.751777,"marketCap":79264142},{"date":"2025-09-05","current":-2.017509,"twenty":-3.626938,"median":-2.538234,"eighty":-1.751639,"marketCap":106362994},{"date":"2025-09-12","current":-1.872294,"twenty":-3.62668,"median":-2.538033,"eighty":-1.751777,"marketCap":99588281},{"date":"2025-09-19","current":-1.738574,"twenty":-3.62668,"median":-2.538033,"eighty":-1.741257,"marketCap":92813568},{"date":"2025-09-26","current":-1.652681,"twenty":-3.62668,"median":-2.538033,"eighty":-1.733002,"marketCap":87393797},{"date":"2025-10-03","current":-1.764269,"twenty":-3.62668,"median":-2.538033,"eighty":-1.729865,"marketCap":93491039},{"date":"2025-10-10","current":-1.888603,"twenty":-3.62668,"median":-2.538033,"eighty":-1.729865,"marketCap":98910809},{"date":"2025-10-17","current":-1.589181,"twenty":-3.62668,"median":-2.538033,"eighty":-1.715896,"marketCap":84006441},{"date":"2025-10-24","current":-1.572126,"twenty":-3.62668,"median":-2.538033,"eighty":-1.710768,"marketCap":82651498},{"date":"2025-10-31","current":-1.707503,"twenty":-3.62668,"median":-2.536982,"eighty":-1.708857,"marketCap":89426211},{"date":"2025-11-07","current":-1.555866,"twenty":-3.62668,"median":-2.534146,"eighty":-1.707448,"marketCap":81296556},{"date":"2025-11-14","current":-1.842931,"twenty":-3.62668,"median":-2.532153,"eighty":-1.706843,"marketCap":86038855},{"date":"2025-11-21","current":-1.683561,"twenty":-3.62668,"median":-2.529404,"eighty":-1.704879,"marketCap":77909199},{"date":"2025-11-28","current":-1.835231,"twenty":-3.62668,"median":-2.52731,"eighty":-1.704879,"marketCap":85361383},{"date":"2025-12-05","current":-1.593453,"twenty":-3.62668,"median":-2.52731,"eighty":-1.699337,"marketCap":74521843},{"date":"2025-12-12","current":-1.46602,"twenty":-3.62668,"median":-2.519124,"eighty":-1.679502,"marketCap":69102072},{"date":"2025-12-19","current":-1.524944,"twenty":-3.62668,"median":-2.509756,"eighty":-1.667406,"marketCap":71811957},{"date":"2025-12-26","current":-1.634642,"twenty":-3.62668,"median":-2.502779,"eighty":-1.658358,"marketCap":77231728},{"date":"2026-01-02","current":-1.452671,"twenty":-3.62668,"median":-2.494862,"eighty":-1.654063,"marketCap":68424601},{"date":"2026-01-09","current":-1.580071,"twenty":-3.62668,"median":-2.49125,"eighty":-1.646849,"marketCap":73844371},{"date":"2026-01-16","current":-1.455182,"twenty":-3.615874,"median":-2.479169,"eighty":-1.636099,"marketCap":67747130},{"date":"2026-01-23","current":-1.480915,"twenty":-3.615874,"median":-2.472232,"eighty":-1.62913,"marketCap":69779543},{"date":"2026-01-30","current":-1.306377,"twenty":-3.615874,"median":-2.463946,"eighty":-1.611667,"marketCap":62510276},{"date":"2026-02-06","current":-1.182562,"twenty":-3.615874,"median":-2.454336,"eighty":-1.599547,"marketCap":55918481},{"date":"2026-02-13","current":-1.183431,"twenty":-3.615874,"median":-2.437007,"eighty":-1.592464,"marketCap":56318189},{"date":"2026-02-20","current":-1.253127,"twenty":-3.593673,"median":-2.426574,"eighty":-1.590155,"marketCap":59129695},{"date":"2026-02-27","current":-1.333814,"twenty":-3.582235,"median":-2.418167,"eighty":-1.586876,"marketCap":63092902},{"date":"2026-03-06","current":-1.344198,"twenty":-3.559755,"median":-2.407629,"eighty":-1.575542,"marketCap":62334134},{"date":"2026-03-13","current":-1.437495,"twenty":-3.516775,"median":-2.396656,"eighty":-1.571306,"marketCap":66453159},{"date":"2026-03-20","current":-1.170912,"twenty":-3.481466,"median":-2.375348,"eighty":-1.561292,"marketCap":61622789},{"date":"2026-03-27","current":-1.277353,"twenty":-3.462757,"median":-2.363742,"eighty":-1.557873,"marketCap":67232358},{"date":"2026-04-02","current":-1.239124,"twenty":-3.455746,"median":-2.356018,"eighty":-1.553395,"marketCap":65280451},{"date":"2026-04-10","current":-1.394796,"twenty":-3.431158,"median":-2.353016,"eighty":-1.543577,"marketCap":74461644},{"date":"2026-04-17","current":-1.614359,"twenty":-3.363623,"median":-2.3395,"eighty":-1.541148,"marketCap":86751430},{"date":"2026-04-24","current":-2.109788,"twenty":-3.344491,"median":-2.322895,"eighty":-1.541148,"marketCap":112776860},{"date":"2026-05-01","current":-2.795263,"twenty":-3.321769,"median":-2.31439,"eighty":-1.541148,"marketCap":149646218},{"date":"2026-05-08","current":-3.792913,"twenty":-3.30237,"median":-2.31439,"eighty":-1.541148,"marketCap":191576076},{"date":"2026-05-15","current":-6.998494,"twenty":-3.321769,"median":-2.31439,"eighty":-1.541148,"marketCap":350557004},{"date":"2026-05-22","current":-7.317402,"twenty":-3.339281,"median":-2.31439,"eighty":-1.541148,"marketCap":363813361},{"date":"2026-05-29","current":-7.00993,"twenty":-3.34626,"median":-2.314381,"eighty":-1.541012,"marketCap":350557004},{"date":"2026-06-05","current":-5.905114,"twenty":-3.362489,"median":-2.31439,"eighty":-1.541148,"marketCap":294585718},{"date":"2026-06-12","current":-5.004121,"twenty":-3.362489,"median":-2.31439,"eighty":-1.541148,"marketCap":247452003},{"date":"2026-06-18","current":-5.442995,"twenty":-3.362489,"median":-2.31439,"eighty":-1.541148,"marketCap":268073003},{"date":"2026-06-26","current":-5.60795,"twenty":-3.359109,"median":-2.314381,"eighty":-1.541012,"marketCap":273964717},{"date":"2026-07-02","current":-6.988224,"twenty":-3.359109,"median":-2.314381,"eighty":-1.541012,"marketCap":343192361},{"date":"2026-07-10","current":-6.185501,"twenty":-3.36855,"median":-2.314381,"eighty":-1.541012,"marketCap":303423289},{"date":"2026-07-17","current":-5.730511,"twenty":-3.441547,"median":-2.314381,"eighty":-1.541012,"marketCap":281329360},{"date":"2026-07-24","current":-5.222528,"twenty":-3.469688,"median":-2.314381,"eighty":-1.541012,"marketCap":254816646},{"date":"2026-07-31","current":-5.127989,"twenty":-3.54332,"median":-2.314372,"eighty":-1.540877,"marketCap":253343717},{"date":"2026-08-07","current":-5.616396,"twenty":-3.652622,"median":-2.314372,"eighty":-1.540877,"marketCap":253343717},{"date":"2026-08-14","current":-6.559138,"twenty":-3.743947,"median":-2.314372,"eighty":-1.540877,"marketCap":296210124},{"date":"2026-08-21","current":-6.51116,"twenty":-3.79146,"median":-2.314372,"eighty":-1.540877,"marketCap":297683806},{"date":"2026-08-28","current":-7.335799,"twenty":-3.872268,"median":-2.314372,"eighty":-1.540877,"marketCap":334525861},{"date":"2026-09-04","current":-7.223324,"twenty":-3.96078,"median":-2.314372,"eighty":-1.540877,"marketCap":328631132},{"date":"2026-09-11","current":-6.637188,"twenty":-3.989551,"median":-2.314372,"eighty":-1.540877,"marketCap":302104853}],"updateTime":1789431570599},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IFRX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624761515","title":"Guggenheim Reaffirms Their Buy Rating on InflaRx (IFRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624761515","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624761515?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:35","pubTimestamp":1775046927,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Yatin Suneja from Guggenheim maintained a Buy rating on InflaRx, with a price target of $14.00. The company’s share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-inflarx-ifrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-inflarx-ifrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623317712","title":"InflaRx presents vilobelimab data","url":"https://stock-news.laohu8.com/highlight/detail?id=2623317712","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623317712?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:10","pubTimestamp":1774872623,"startTime":"0","endTime":"0","summary":"InflaRx (IFRX) announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum were featured in an oral presentation during the l...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inflarx-presents-vilobelimab-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inflarx-presents-vilobelimab-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623144563","title":"InflaRx vilobelimab Phase 3 pyoderma gangrenosum trial ends early for futility","url":"https://stock-news.laohu8.com/highlight/detail?id=2623144563","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623144563?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:32","pubTimestamp":1774870346,"startTime":"0","endTime":"0","summary":"InflaRx highlighted Phase 3 vilobelimab data in pyoderma gangrenosum in a late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting in Denver, held March 27-31.Trial enrolled 54 patients before being stopped early for futility based on Independent Data Monitoring Committee recommendation.Primary endpoint of complete target ulcer closure reached 20.8% on vilobelimab versus 16.7% on placebo.Complete disease remission was 20.8% with vilobelimab versus 5.1% with placebo.InflaRx expects any future development work in pyoderma gangrenosum would likely be pursued with a partner.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6SdK2q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4112","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","SG9999014021.USD","IE00BKPKM429.USD","BK4585","IE00BN0W2T93.GBP","IFRX","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4139","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","NDAQ","IE00B64PRP62.GBP","SG9999014013.SGD","BK4588","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620279736","title":"InflaRx Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2620279736","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620279736?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:52","pubTimestamp":1774011120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IFRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2026 08:52 ET (12:52 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620738873","title":"InflaRx price target lowered to $14 from $22 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738873","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738873?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:20","pubTimestamp":1774005614,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Yatin Suneja lowered the firm’s price target on InflaRx (IFRX) to $14 from $22 and keeps a Buy rating on the shares. The firm co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inflarx-price-target-lowered-to-14-from-22-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inflarx-price-target-lowered-to-14-from-22-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620205141","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: InflaRx (IFRX) and Kuros Biosciences (OtherCSBTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620205141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620205141?lang=en_us&edition=fundamental","pubTime":"2026-03-20 09:40","pubTimestamp":1773970808,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on InflaRx (IFRX) and Kuros Biosciences (CSBTF). InflaRx (IFRX) Life...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-inflarx-ifrx-and-kuros-biosciences-othercsbtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-inflarx-ifrx-and-kuros-biosciences-othercsbtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LU0128526141.USD","XBI","BK4585","HCSG","IFRX","BK4581","CSBTF","XLV","BK4588","LU0029874061.USD","LABU","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620252062","title":"InflaRx NV reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620252062","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620252062?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:31","pubTimestamp":1773927108,"startTime":"0","endTime":"0","summary":"InflaRx NV reports results for the quarter ended December 31 - Earnings SummaryInflaRx NV IFRX.OQ reported a quarterly adjusted loss of 15 cents per share for the quarter ended December 31, lower than","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL8N4071MH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427902","title":"InflaRx Q4 EPS $(0.17) Beats $(0.18) Estimate, Sales $(39.501K) Miss $230.000K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427902","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620427902?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:45","pubTimestamp":1773920741,"startTime":"0","endTime":"0","summary":"InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 88.89 percent decrease over losses of $(0.09) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51350166/inflarx-q4-eps-0-17-beats-0-18-estimate-sales-39-501k-miss-230-000k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620924247","title":"InflaRx reports FY25 EPS (EUR 0.68) vs. (EUR 0.78) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620924247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620924247?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:35","pubTimestamp":1773920154,"startTime":"0","endTime":"0","summary":"Reports revenue EUR 29.3M vs. EUR 165.8M last year. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx (IFRX), said: “With th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inflarx-reports-fy25-eps-eur-0-68-vs-eur-0-78-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inflarx-reports-fy25-eps-eur-0-68-vs-eur-0-78-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620124269","title":"InflaRx FY 2025 net loss narrows 9.8% to EUR 45.63 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620124269","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620124269?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:32","pubTimestamp":1773919948,"startTime":"0","endTime":"0","summary":"InflaRx published a full-year earnings release reporting a net loss of EUR 45.63 million and revenue of EUR 29,331.Cost of sales rose 119.1% to EUR 7.27 million, driven mainly by EUR 4 million in higher inventory write-downs after scaling back and discontinuing GOHIBIC sales activities in the U.S.Research and development expense fell 27.2% to EUR 25.72 million, primarily due to lower manufacturing development and clinical trial third-party costs.Cash, cash equivalents and marketable securities totaled EUR 46.2 million, and the company said this is expected to fund operations to mid-2027.Management said it is prioritizing izicopan after positive Phase 2a topline data in hidradenitis suppurativa and chronic spontaneous urticaria, expects to conclude FDA discussions on a Phase 2b HS trial in the coming months, and plans a PK bridging study in China this year.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbJL1fR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","BK4139","IFRX","LU0314104364.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","NDAQ","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4588","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","SG9999014039.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429292","title":"Press Release: InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429292","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429292?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919800,"startTime":"0","endTime":"0","summary":"-- Promising Phase 2a data announced for izicopan, underscoring its. potential as a meaningfully differentiated, effective and safe oral. -- Substantial progress made toward Phase 2b readiness for izicopan in. -- InflaRx actively reviewing and considering additional development in. its potential in HS, AAV and select additional I&I indications. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: \"With the strong Phase 2a results reported in hidradenitis suppurativa and chronic spontaneous urticaria, and its best-in-class potential, we made the strategic decision to focus our resources on izicopan. We are in active discussions with the FDA for the design of our Phase 2b trial in HS and look forward to establishing a clear path forward soon. By tightly focusing the Company on izicopan in select inflammation and immunology indications, we believe we are well positioned to advance to the next stage of development and effectively execute our plans.\". Complete Pha","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014542.SGD","LU1868837136.USD","BK4585","GB00BDT5M118.USD","IE00B3T34201.USD","IE00BLSP4239.USD","PG","LU2129689431.USD","IE00B1XK9C88.USD","LU2129689514.USD","LU0237698245.USD","LU2552382215.SGD","LU0640476718.USD","LU0323591593.USD","BK4559","SG9999014559.SGD","IE00BN8TJ469.HKD","BK4139","LU2242652126.USD","SG9999014575.USD","BK4558","LU2097829019.USD","LU0689626769.HKD","LU2552382132.HKD","LU1868837300.USD","LU1868836591.USD","IE000M9KFDE8.USD","LU0942090050.USD","SG9999002224.SGD","IFRX","LU1914381329.SGD","LU2552382058.USD","LU1280957306.USD","LU0094547139.USD","LU0320765646.SGD","LU1868836757.USD","BK4504","LU0061475181.USD","SG9999002232.USD","IE00BWXC8680.SGD","LU0234572021.USD","LU0234570918.USD","LU0868494708.USD","BK4181","PK","BK4567","LU1430594728.SGD","LU0868494617.USD","IE00BLSP4452.SGD","SG9999015341.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253492","title":"InflaRx N.V. Director Mark Kubler Files Initial Statement of Beneficial Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253492","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253492?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:17","pubTimestamp":1773836232,"startTime":"0","endTime":"0","summary":"InflaRx reported an initial statement of beneficial ownership by director Mark Kubler. Kubler reported direct beneficial ownership of 0.96 million ordinary shares. He also reported stock options covering 7,308 ordinary shares with an exercise price of USD 0.0131. Kubler reported additional stock options covering 34,464 ordinary shares with an exercise price of USD 1.86.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL19FGMb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253416","title":"InflaRx N.V. director Anthony S. Gibney files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253416","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253416?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:16","pubTimestamp":1773836206,"startTime":"0","endTime":"0","summary":"Inflarx reported that director Anthony Gibney filed an initial statement of beneficial ownership dated 03/18/2026. The filing shows Anthony Gibney beneficially owns 10,000 ordinary shares directly. It also reports direct stock options covering 11,667 ordinary shares with an exercise price of USD 1.86. The filing lists additional direct stock options covering 30,000 ordinary shares with an exercise price of USD 2.41.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contain","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL80XXTt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620025390","title":"InflaRx N.V. Director Hege Hellstrom Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620025390","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620025390?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:13","pubTimestamp":1773835997,"startTime":"0","endTime":"0","summary":"InflaRx reported an initial statement of beneficial ownership by director Hege Hellstrom. Hellstrom disclosed stock options to buy 22,500 ordinary shares at USD 4.19 per share. The filing also listed options for 30,000 ordinary shares at USD 1.79 per share. Additional options covered 30,000 ordinary shares at USD 2.41 per share. A further option was for 30,000 ordinary shares at USD 1.17 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2qwMZT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253938","title":"Inflarx Announces Late-Breaker Oral Presentation On Vilobelimab Phase 3 Results In Pyoderma Gangrenosum At 2026 American Academy Of Dermatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253938","media":"Reuters","labels":["productRelease","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253938?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:10","pubTimestamp":1773835811,"startTime":"0","endTime":"0","summary":"March 18 (Reuters) - InflaRx NV ::*INFLARX ANNOUNCES LATE-BREAKER ORAL PRESENTATION ON VILOBELIMAB PHASE 3 RESULTS IN PYODERMA GANGRENOSUM AT 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING  ((Reu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nRSD91lM5f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253963","title":"InflaRx N.V. Chief Scientific Officer Guo Renfeng files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253963","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253963?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:10","pubTimestamp":1773835804,"startTime":"0","endTime":"0","summary":"InflaRx reported an initial statement of beneficial ownership for Guo Renfeng, a director and Chief Scientific Officer. Guo Renfeng reported direct ownership of 1.76 million ordinary shares. The filing also reported stock options to buy ordinary shares totaling 0.97 million shares at an exercise price of USD 1.86. It also listed stock options for 0.57 million shares at USD 1.17 and 500,000 shares at USD 2.41.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained ther","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL828qsw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253936","title":"InflaRx N.V. SVP Derval OCarroll Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253936","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253936?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:09","pubTimestamp":1773835777,"startTime":"0","endTime":"0","summary":"InflaRx reported an initial statement of beneficial ownership for Derval OCarroll, Senior Vice President and Global Head of Regulatory Affairs and Compliance. The filing listed stock options covering 251,000 ordinary shares with exercise prices ranging from USD 1.17 to USD 2.44.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9qf3Rj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IFRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620825363","title":"InflaRx CEO and Director Niels Riedemann Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825363","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825363?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:07","pubTimestamp":1773835654,"startTime":"0","endTime":"0","summary":"InflaRx reported an initial statement of beneficial ownership for Niels Riedemann, a director and chief executive officer. Riedemann beneficially owned 1.07 million ordinary shares directly. The filing also listed stock options covering 635,000 ordinary shares with an exercise price of USD 1.17. It included a performance stock option covering 190,500 ordinary shares with an exercise price of USD 1.17.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL18n7yq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620225352","title":"InflaRx NV CFO Thomas Taapken files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225352","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620225352?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:06","pubTimestamp":1773835613,"startTime":"0","endTime":"0","summary":"InflaRx reported an initial statement of beneficial ownership for Thomas Taapken, its chief financial officer. The filing shows Thomas Taapken beneficially owned 3,500 ordinary shares directly. It also reports indirect stock options covering 1.27 million ordinary shares through tomtaa. Exercise prices listed for the options include USD 1.86 and USD 2.44.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6tMmZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620230493","title":"InflaRx to present Phase 3 vilobelimab data in pyoderma gangrenosum at AAD annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620230493","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620230493?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:31","pubTimestamp":1773833476,"startTime":"0","endTime":"0","summary":"InflaRx will give a late-breaking oral presentation at the American Academy of Dermatology Annual Meeting, held March 27-31, 2026, in Denver. The presentation, delivered by Benjamin Kaffenberger, is scheduled for March 28, 2026, from 2:24-2:36 PM MT at Bellco Theatre 3.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL53v656:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IFRX","SG9999014005.SGD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4112","LU0314104364.USD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4139","LU2095319765.USD","IE00BGHQF748.EUR","BK4588","NDAQ","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":60,"code":"91000000","status":"200"}]}}